<DOC>
	<DOC>NCT03003884</DOC>
	<brief_summary>The purpose of this study is to find out the optimal dose for Remimazolam Tosilate as a procedural sedative during a diagnostic upper GI endoscopy and to assess its efficacy and safety profile comparing to propofol.</brief_summary>
	<brief_title>A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy</brief_title>
	<detailed_description>This is an multi-center,single-blinded,parallel-group,dose-finding study using Remimazolam or propofol for sedation in patients undergoing diagnostic upper GI endoscopy.Subjects are randomized to different treatment groups (including 4 for Remimazolam Tosilate and 1 for propofol).Lidocaine and fentanyl are permitted during a diagnostic upper GI endoscopy.Efficacy and safety profiles of Remimazolam Tosilate are to be evaluated.</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<criteria>subjects aged 1860 years； intending to undergo diagnostic upper GI endoscopy ASA( American Society of Anesthesiologists) I or II； 18 kg/m²&lt;BMI(Body Mass Index)&lt;30 kg/m². Patients with a suspected upper GI bleed an conditions predisposing to hemorrhage at the discretion of the investigator; one or more of the laboratory findings fall out of the limitations for this study(platelet,hemoglobin,aspartate aminotransferase,etc.); history of recent use of narcotics,analgesics,anaesthetics and benzodiazepine hypnotics; history of severe cardiovascular disease; cerebral disease or mental disorder; allergic to drugs used in the study; pregnant women or those in lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>